文献速递慢性肾脏病

蛋白质氨甲酰化与慢性肾功能不全队列研究中慢性肾脏病进展的关系

Protein carbamylation and chronic kidney disease progression in the Chronic Renal Insufficiency Cohort Study.
PubMed 文献 · Nephrol Dial Transplant · 2021-01-01

在慢性肾功能不全队列研究中开展两项巢式病例对照研究,分别匹配75对CKD进展病例与对照、75对死亡病例与存活对照,比较基线氨甲酰化白蛋白水平。结果显示C-Alb最高三分位与CKD进展风险显著增加相关(OR=7.9),与死亡风险关联较小(OR=3.4)。提示蛋白质氨甲酰化可预测CKD进展,独立于eGFR和蛋白尿等传统危险因素。

要点

  • 基线C-Alb最高三分位者CKD进展风险显著增加(OR=7.9)。
  • C-Alb与死亡风险关联较小且样本量有限(OR=3.4,P=0.05)。
  • C-Alb与eGFR相关,但与BUN相关性更强。

核心结论

  • 蛋白质氨甲酰化可预测CKD进展,独立于eGFR和蛋白尿等传统危险因素。
  • 氨甲酰化与死亡的关联在有限样本中较小。

研究设计与样本

  • 在慢性肾功能不全队列研究中开展两项巢式病例对照研究。
  • 第一项研究匹配75例CKD进展病例与75例对照,匹配因素为基线eGFR、24小时蛋白尿、年龄、性别和种族。
  • 第二项研究匹配75例随访期间死亡者与75例存活对照。
  • 比较各组基线氨甲酰化白蛋白(C-Alb)水平。

主要发现

  • CKD进展研究中,除BUN和吸烟状态外,匹配及其他参数均无显著差异。
  • 死亡研究中,基线唯一差异为吸烟状态。
  • 校正基线差异后,C-Alb最高三分位与最低三分位相比,CKD进展风险增加(OR=7.9;95%CI 1.9-32.8;P=0.004)。
  • C-Alb最高三分位与最低三分位相比,死亡风险增加(OR=3.4;95%CI 1.0-11.4;P=0.05)。
  • C-Alb与eGFR相关,但与BUN相关性更强。

临床怎么用

  • C-Alb可能作为CKD进展的预测标志物,但需进一步验证。

局限性

  • 死亡分析样本量有限,关联较小。
  • 研究为巢式病例对照设计,需外部队列验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Protein carbamylation is a post-translational protein modification caused, in part, by exposure to urea's dissociation product cyanate. Carbamylation is linked to cardiovascular outcomes and mortality in dialysis-dependent end-stage kidney disease (ESKD), but its effects in earlier pre-dialysis stages of chronic kidney disease (CKD) are not established. METHODS: We conducted two nested case-control studies within the Chronic Renal Insufficiency Cohort Study. First, we matched 75 cases demonstrating CKD progression [50% estimated glomerular filtration rate (eGFR) reduction or reaching ESKD] to 75 controls (matched on baseline eGFR, 24-h proteinuria, age, sex and race). In the second study, we similarly matched 75 subjects who died during follow-up (cases) to 75 surviving controls. Baseline carbamylated albumin levels (C-Alb, a validated carbamylation assay) were compared between cases and controls in each study. RESULTS: At baseline, in the CKD progression study, other than blood urea nitrogen (BUN) and smoking status, there were no significant differences in any matched or other parameter. In the mortality group, the only baseline difference was smoking status. Adjusting for baseline differences, the top tertile of C-Alb was associated with an increased risk of CKD progression [odds ratio (OR) = 7.9; 95% confidence interval (CI) 1.9-32.8; P = 0.004] and mortality (OR = 3.4; 95% CI 1.0-11.4; P = 0.05) when compared with the bottom tertile. C-Alb correlated with eGFR but was more strongly correlated with BUN. CONCLUSIONS: Our data suggest that protein carbamylation is a predictor of CKD progression, beyond traditional risks including eGFR and proteinuria. Carbamylation's association with mortality was smaller in this limited sample size.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Kalim S, Berg AH, Karumanchi SA, et al. Protein carbamylation and chronic kidney disease progression in the Chronic Renal Insufficiency Cohort Study. Nephrol Dial Transplant. 2021. PMID: 33661286. doi:10.1093/ndt/gfaa347

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。